High-performance liquid chromatography-mass spectrometry-based serum metabolic profiling in patients with HBV-related hepatocellular carcinoma.
10.12122/j.issn.1673-4254.2019.01.08
- Author:
Lei ZHANG
1
;
Zhijuan FAN
2
;
Hua KANG
2
;
Yufan WANG
2
;
Shuye LIU
2
;
Zhongqiang SHAN
1
Author Information
1. Chemical Engineering Institute, Tianjin University, Tianjin 300072 China.
2. Clinical Laboratory Department of Tianjin Third Central Hospital, Tianjin Key Laboratory of Artificial Cell, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin 300170 China.
- Publication Type:Journal Article
- Keywords:
hepatitis;
hepatitis B virus;
hepatocellular carcinoma;
liver cirrhosis;
metabonomics
- MeSH:
Carcinoma, Hepatocellular;
blood;
diagnosis;
virology;
Case-Control Studies;
Chromatography, High Pressure Liquid;
DNA, Viral;
blood;
Hepatitis B virus;
genetics;
Hepatitis B, Chronic;
blood;
virology;
Humans;
Liver Cirrhosis;
virology;
Liver Neoplasms;
blood;
diagnosis;
virology;
Mass Spectrometry;
Metabolome;
Metabolomics;
ROC Curve
- From:
Journal of Southern Medical University
2019;39(1):49-56
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the diagnostic value of the serum metabolites identified by high-performance liquid chromatography-mass spectrometry (HPLC/MS) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
METHODS:A total of 126 patients admitted to Tianjin Third Central Hospital were enrolled, including 27 patients with HBV-related hepatitis with negative viral DNA (DNA-N), 24 with HBV-related hepatitis with positive viral DNA, 24 with HBV-related liver cirrhosis, 27 with HBV-related HCC undergoing surgeries or radiofrequency ablation, and 24 with HBV-related HCC receiving interventional therapy, with 25 healthy volunteers as the normal control group. Serum samples were collected from all the subjects for HPLC/MS analysis, and the data were pretreated to establish an orthogonal partial least- squares discriminant analysis (OPLS-DA) model. The differential serum metabolites were preliminarily screened by comparisons between the HBV groups and the control group, and the characteristic metabolites were identified according to the results of non-parametric test. The potential clinical values of these characteristic metabolites were evaluated using receiver operator characteristic curve (ROC) analysis.
RESULTS:A total of 25 characteristic metabolites were identified in the HBV- infected patients, including 9 lysophosphatidylcholines, 2 fatty acids, 17α-estradiol, sphinganine, 5-methylcytidine, vitamin K2, lysophosphatidic acid, glycocholic acid and 8 metabolites with few reports. The patients with HBV- related HCC showed 22 differential serum metabolites compared with the control group, 4 differential metabolites compared with patients with HBV-related liver cirrhosis; 10 differential metabolites were identified in patients with HBV-related HCC receiving interventional therapy compared with those receiving surgical resection or radiofrequency ablation. From the normal control group to HBV-related HCC treated by interventional therapy, many metabolites underwent variations following a similar pattern.
CONCLUSIONS:We identified 25 characteristic metabolites in patients with HBV-related HCC, and these metabolites may have potential clinical values in the diagnosis of HBV-related HCC. The continuous change of some of these metabolites may indicate the possibility of tumorigenesis, and some may also have indications for the choice of surgical approach.
